High Interval Versus Moderate Intensity Continuous Training on Soluble st2 Biomarkers in Chronic Heart Failure

October 15, 2024 updated by: Dina Reda Ali, Cairo University
This study was designed to compare between the effect of high intensity interval training (HIIT) and moderate intensity continuous training (MICT) on soluble ST2 biomarkers among chronic heart failure patients, also measure the improvement in the quality of life with different modes of exercise and with of it is more benifitial for the heart failure patient

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The data concerned with the study including soluble ST2 biomarker levels, ejection fraction and MLHFQ was measured before and after twelve weeks of treatment.In this study a total sixty male patients with chronic heart failure NYHA class (I &II) were selected from the outpatient clinic, El-Demerdash hospital, Ain-shams University. Their age ranged from 50-60 years. Patients were randomly assigned into two groups, group A receiving HIIT along with prescribed medical treatment and group B receiving MCT along with prescribed medical treatment.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Giza, Egypt, 0000
        • Faculty of Physical Therapy Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • The patients selection was according to the following criteria:

    • Patients diagnosed with chronic heart failure (New York heart association class I& II) with systolic left ventricular dysfunction.
    • Their left ventricular ejection fraction (LVEF) <40%.
    • Medical treatment was optimized at least three months prior to study entry.
    • All patients didn't participate in any rehabilitation programs prior to the study.

Exclusion Criteria:

  • Patients who had met one of the following criteria were excluded from the study:

    1. Signs of acute heart failure, unstable angina or severe arrhythmia three months prior to enrolment in the study.
    2. Pacemakers.
    3. Chronic obstructive pulmonary disease.
    4. Other disorders counteracting exercise testing conditions that limit lower limb mobility (for example, burns, fractures)
    5. Pre-existing neuromuscular diseases (for example Myasthenia Gravis).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group A
high intensity interval training

Frequency: HIIT will be in 2 supervised sessions per week for 12 weeks on the treadmill.

session duration from 30-40 min including the waming up and cooling down Intensity: HIIT included 4 minute intervals aiming 60-85% of heart rate reserve

Experimental: group B
moderate intensity continuous training

Frequency: Moderate continuous training is scheduled 2 times per week for 12 weeks.

Intensity: exercise had been applied on the treadmill with 40%-59% of heart rate reserve) session duration from 30-40 min including the warming up and cooling down

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
soluble ST2 biomarker level
Time Frame: before the start of the trail and at the end of the trail 3 months
sample was taken at the cubited vein at the beginning of the program and also at its end
before the start of the trail and at the end of the trail 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ejection fraction
Time Frame: before the start of the trail and at the end of the trail 3 months
Left ventricular systolic dysfunction was assessed using the ejection fraction by 2D simpson method
before the start of the trail and at the end of the trail 3 months
mannisota of daily living questionnaire score
Time Frame: before the start of the trail and at the end of the trail 3 months
The twenty one item questionnaire was usedfrom 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.
before the start of the trail and at the end of the trail 3 months
peak exercise response
Time Frame: before the start of the trail and at the end of the trail 3 months
monitoring the peak exercise response
before the start of the trail and at the end of the trail 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Donia M Elmasry, Doctorate, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2022

Primary Completion (Actual)

August 20, 2023

Study Completion (Actual)

October 16, 2023

Study Registration Dates

First Submitted

June 14, 2024

First Submitted That Met QC Criteria

October 15, 2024

First Posted (Actual)

October 18, 2024

Study Record Updates

Last Update Posted (Actual)

October 18, 2024

Last Update Submitted That Met QC Criteria

October 15, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P.T.REC/012/004017

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

study protocol and final results

IPD Sharing Time Frame

August 2024 till December 2024

IPD Sharing Access Criteria

researchers

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Subscribe